The global fluorescence in situ hybridization imaging systems market size is expected to reach USD 2.14 billion by 2030, expanding at a CAGR of 8.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. Increasing R&D investments pertaining to in vitro diagnostics are expected to drive the Fluorescence In Situ Hybridization (FISH) imaging systems market. The presence of government organizations, such as the European Diagnostic Manufacturers Association that focuses on the development and growth of the in vitro diagnostics market in Europe, is also contributing to growth.

Furthermore, FISH imaging systems are gaining popularity in diagnostics for the determination of suspected diseases caused by pathogens or bacteria. Increasing incidence of genetic diseases, such as lymphoma, solid tumors, leukemia, autism, and other developmental syndromes, is also expected to boost adoption. Growing penetration of fluoroscopy, microscopes, illuminators, and CCD cameras in testing for infectious diseases is expanding growth opportunities for these systems. Increasing prevalence of diseases with chromosomal aberrations, such as cancer and genetic abnormalities, as well as unmet diagnostic & clinical needs in developing countries, is anticipated to drive the market.

Moreover, increasing demand for rapid, sensitive, & accurate diagnostic techniques for validation of diseases, coupled with rising awareness, increase in healthcare expenditure, and extensive R&D for the development of novel imaging systems are also expected to drive growth over the forecast period.

Request a free sample copy or view report summary: Fluorescence In Situ Hybridization Imaging Systems Market Report

Fluorescence In Situ Hybridization Imaging Systems Market Report Highlights

• Instruments held the largest market, whereas FISH imaging services are expected to grow at the fastest rate during the forecast period

• At present, the market penetration of FISH imaging in cancer diagnostics is very high, hence the diagnostic laboratories segment accounted for larger revenues

• Cancer diagnosis held the largest revenue share owing to increasing incidence of cancer, thus fueling the adoption of FISH imaging systems

• Among end-use segments, companion diagnostics is expected to witness faster growth than research and diagnostic segments

• Diagnostic laboratories held the dominant position in 2016 as these systems are predominantly used in various clinical studies for visualization of precancerous lesions in cervical cancer, assessing the risk of human papillomavirus, and for detection of leukemia, myelodysplastic syndrome, multiple myeloma, & chromosomal abnormalities

• North America held the largest revenue share owing to extensive adoption of these solutions in research and development across this region

• Asia Pacific is anticipated to exhibit lucrative CAGR over the forecast period due to the increase in investments by manufacturers & governments, supportive government initiatives in the biotechnology sector, and the presence of a large number of untapped opportunities

• The industry is highly competitive with a limited number of players holding a majority of the overall revenues. Some of the most notable market participants are Euroclone SpA, TissueGnostics GmbH, Agilent Technologies, Inc., Abnova Taiwan Corp, BioGenex Laboratories Inc., o Bio-View Ltd and General Electric Company. They account for a considerable share of the industry

Fluorescence In Situ Hybridization Imaging Systems Market Segmentation

Grand View Research has segmented the global fluorescence in situ hybridization imaging systems market based on component, deployment, end-use, and region:

Fluorescence In Situ Hybridization Imaging Systems Product Outlook (Revenue, USD Million, 2018 - 2030)

• Instruments

  • Microscopes

  • Automated Cell Analyzers

  • Others

• Consumables & Accessories

• Services

• Software

Fluorescence In Situ Hybridization Imaging Systems Application Outlook (Revenue, USD Million, 2018 - 2030)

• Cancer Diagnosis

  • Lung Cancer

  • Breast Cancer

  • Others

• Genetic Disease Diagnosis

• Others

Fluorescence In Situ Hybridization Imaging Systems End Use Outlook (Revenue, USD Million, 2018 - 2030)

• Diagnostic Laboratories

• Research & Academic Institutes

• Others

Fluorescence In Situ Hybridization Imaging Systems Regional Outlook (Revenue, USD Million; 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• APAC

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• MEA

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in Fluorescence In Situ Hybridization Imaging Systems Market

• Euroclone SpA

• TissueGnostics GmbH

• Agilent Technologies, Inc.

• Abnova Taiwan Corp

• BioGenex Laboratories Inc

• Leica Biosystems Nussloch GmbH

• Bio-View Ltd

• Thermo Fisher Scientific Inc

• MetaSystems Probes GmbH